Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Ogura (Kanagawa, Japan), Y. Nishioka (Tokushima, Japan), T. Saito (Ibaraki, Japan), K. Tomii (Hyogo, Japan), K. Kamio (Tokyo, Japan), H. Tomioka (Hyogo, Japan), S. Hisata (Tochigi, Japan), S. Sakamoto (Tokyo, Japan), T. Handa (Kyoto, Japan), Y. Miyazaki (Tokyo, Japan), S. Homma (Tokyo, Japan), A. Azuma (Tokyo, Japan). Late Breaking Abstract - Phase 2, multi-center, open label, single-arm study of TAS-115, a novel multi-kinase inhibitor in patients with idiopathic pulmonary fibrosis. 1296

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 Late Breaking Abstract - Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof of concept clinical trial Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 Late Breaking Abstract - Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease - COPD-ST2OP: a phase IIa, placebo-controlled trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Design of phase II, randomized, placebo-controlled study of loratadine associate with rapamycin in patients with lymphangioleiomyomatosis (LAM) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) Source: Eur Respir J, 52 (6) 1801130; 10.1183/13993003.01130-2018 Year: 2018 Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial. Source: International Congress 2017 – Interstitial lung diseases (ILDs): novel pathogenetic pathways Year: 2017 Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022 RCT Abstract - Using a smartphone application in COPD patients to increase physical activity following pulmonary rehabilitation. Results of the AMOPUR Study, a multicenter, randomized, controlled study Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases Year: 2021 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021